Additional file 2: of Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Figure S1. Vemurafenib Ctrough concentrations (mean ± SD) after day 28 in the pharmacokinetics and expansion cohorts. SD standard deviation, CV coefficient of variation. (PDF 71 kb)